Arch Therapeutics completes direct public offering

On Feb. 21, hemostasis company Arch Therapeutics Inc. (OTCQB:ARTH) raised $6.1 million through the sale of 10.2 million units at $0.60 in a registered direct offering with six accredited investors. E...